Research programme: oral film benign prostatic hyperplasia therapeutics - IntelGenx

Drug Profile

Research programme: oral film benign prostatic hyperplasia therapeutics - IntelGenx

Alternative Names: INT0025; INT0025/2010; INT0026; INT0026/2011

Latest Information Update: 23 Dec 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator IntelGenx Corp.
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Benign prostatic hyperplasia

Most Recent Events

  • 12 Dec 2013 No development reported - Preclinical for Benign prostatic hyperplasia in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top